Our top stories

World Summit of AI 2019

January 15, 2021

AACR

We attended Session PO.IM02.07 and presented EXS21546, our non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy (Poster 1731)

Recognition

This year Exscientia have received the Queen's Award for Innovation, FT1000 & Alantra Pharma Fast50 awards.

Nothing yet